Skip to content

Study · Non-randomized trial · n = 11 · 1985

3 results

Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma.

degli Uberti EC, Trasforini G, Salvadori S, Margutti A, Rotola C, Bianconi M, Teodori V, Tomatis R, Pansini R

Metabolism: clinical and experimental1 Sept 1985Cited by 4 (Europe PMC)

PMID4033428 (opens in a new tab)DOI10.1016/0026-0495(85)90113-1 (opens in a new tab)PepBankPUB-04033428
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with prolactin-secreting pituitary adenoma, dermorphin produced no prolactin response.

    In plain wordsIn patients with prolactin-secreting pituitary tumors, dermorphin produced no prolactin response.

    Peptide
    Dermorphin
    Outcome
    No significant changeProlactin response
    Study

    n = 11

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No PRL response to D was observed in all 11 patients.
    1 context sentence
    Summary · context
    In 11 patients with a PRL-secreting pituitary adenoma (eight microprolactinomas and three macroprolactinomas with suprasellar extension),
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with prolactin-secreting pituitary adenoma, growth hormone increased after dermorphin except in those with macroprolactinoma.

    In plain wordsIn patients with prolactin-secreting pituitary tumors, dermorphin increased growth hormone except in those with large tumors.

    Peptide
    Dermorphin
    Outcome
    IncreaseGrowth hormone response without macroprolactinoma
    Study

    n = 8

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma GH increased after D in all patients, except in three patients bearing a macroprolactinoma.
    1 context sentence
    Summary · context
    In 11 patients with a PRL-secreting pituitary adenoma (eight microprolactinomas and three macroprolactinomas with suprasellar extension),
  3. 03HumanNon-randomized trialEfficacy outcome

    In three patients with macroprolactinoma, growth hormone did not increase after dermorphin.

    In plain wordsIn patients with large prolactin-secreting pituitary tumors, growth hormone did not increase after dermorphin.

    Peptide
    Dermorphin
    Outcome
    No significant changeGrowth hormone response with macroprolactinoma
    Study

    n = 3

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma GH increased after D in all patients, except in three patients bearing a macroprolactinoma.
    1 context sentence
    Summary · context
    In 11 patients with a PRL-secreting pituitary adenoma (eight microprolactinomas and three macroprolactinomas with suprasellar extension),

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.